What Johnson & Johnson Innovation does

Johnson & Johnson Innovation is the corporate venture capital and external innovation arm of Johnson & Johnson (NYSE: JNJ), operating as a private Delaware LLC headquartered in Cambridge, Massachusetts, and established in 2013. The organization runs three interconnected programs: (1) Early Innovation Partnerships, which provides a single point of entry to J&J for early-stage startups and life science innovators via regional teams in Boston, London, South San Francisco, and Shanghai; (2) JJDC, the corporate venture capital unit that invests across pharmaceuticals and medtech at all stages from new company creation and seed through Series A and beyond, including PIPEs; and (3) JLABS, a global life science incubator network of 8 physical and virtual sites providing capital-efficient lab space, expertise, community, and entrepreneurial programming. The portfolio of focus areas spans Innovative Medicine (oncology, immunology, neuroscience, cardiopulmonary) and MedTech (cardiovascular, vision, surgery, orthopaedics), with sub-programs such as Blue Knight (a BARDA collaboration for health security) and QuickFire Challenges.

The underlying technology platform is J&J's own end-to-end capabilities — discovery, clinical development, regulatory affairs, manufacturing, and commercialization — exposed to portfolio companies as a distribution and value-add mechanism. The organization does not sell a product; rather, it deploys capital (over $1.8 billion since 2013 across more than 640 strategic collaborations) and provides non-dilutive resources to startups, generating returns through equity appreciation and preferential deal flow into J&J's therapeutic and medtech business units. Headcount is 11-50 personnel, consistent with a lean CVC-plus-incubation team that relies on J&J's broader enterprise for operating leverage. Notable external indicators of the model include 40+ active JJDC portfolio companies, 380+ JLABS companies with J&J deals or partnerships, and 60+ JLABS graduates that have gone public via IPO or reverse merger.

The business model is best understood as a strategic CVC: capital is allocated for strategic optionality and financial return, with portfolio construction, geographic deployment, and sector focus aligned to J&J's internal business unit demand. The venture team spans Search & Evaluation, Early Innovation Partnering, and New Company Creation across four major geographies. Revenue is not separately reported; the unit's economic value is captured within the parent company's broader R&D and business development allocations rather than as a discrete revenue line.

Name

Johnson & Johnson Innovation

Legal name

Johnson and Johnson Innovation, LLC

Website

https://jnjinnovation.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Short description

Johnson & Johnson Innovation is the corporate venture capital and external innovation arm of Johnson & Johnson, operating Early Innovation Partnerships, the JJDC venture fund, and the JLABS global incubator network to invest in and incubate early-stage life science companies across pharmaceuticals and medtech.

Ownership category

akta.pro rank

Product category

Healthcare Venture Capital and Incubation

NAICS

Management Consulting Services (54161), Other Scientific and Technical Consulting Services (54169)

SIC

Investment Advice (6282), Services-Management Consulting Services (8742)

akta.pro primary industry

Corporate Strategic Partnership & Ecosystem Investment Arms (FSANAHAF)

akta.pro secondary industries

Corporate Venture Studios & Incubators (Build/launch ventures) (FSANAHAC), Corporate Innovation & Technology Scouting Units (with investment mandate) (FSANAHAI)

Keywords

• Healthcare venture capital
• Life science incubator
• Biotech startup partnership
• Pharmaceutical innovation
• Medtech investment

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices9 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Investment capital deployed, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Venture Capital Returns: JJDC invests in early-stage companies with the goal of generating returns through equity appreciation as portfolio companies grow and achieve milestones. Returns support the broader Johnson & Johnson innovation ecosystem.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Johnson & Johnson Innovation operates as the corporate venture capital and external innovation arm of Johnson & Johnson. It provides a single point of entry to Johnson & Johnson's full capabilities (discovery, clinical development, regulatory, manufacturing, commercialization) for early-stage healthcare startups and life science innovators, delivered through three pillars: Early Innovation Partnerships, JJDC venture capital investing across pharmaceuticals and medtech at all stages, and the JLABS global incubator network offering capital-efficient lab space, expertise, and community.

Product overview

Johnson & Johnson Innovation is a platform organization comprising multiple interconnected offerings: JLABS provides global incubation with lab space and resources; JJDC delivers venture capital investment across all stages; QuickFire Challenges crowdsources innovation globally; Early Innovation Partnerships enable strategic collaboration through regional teams; and focus areas cover Innovative Medicine (pharmaceuticals across oncology, immunology, neuroscience, cardiopulmonary) and MedTech (medical devices across cardiovascular, vision, surgery, orthopaedics). The organization serves as a single point of entry for innovators to access Johnson & Johnson's full capabilities including discovery, clinical development, regulatory affairs, manufacturing, and commercialization.

Differentiator

Problem solved

Functional benefit

Brands

• JLABS: Johnson & Johnson's global life science incubator network providing startups with capital-efficient lab space, resources, expertise, community, and entrepreneurial programs
• JJDC
• Blue Knight

Products and services

• JLABS Johnson & Johnson's global incubator network providing startups with capital-efficient lab space, resources including expertise, community, industry connections, and entrepreneurial programs to support the creation of potential healthcare breakthroughs. Includes physical residency and virtual membership options across 8 locations globally.
• JJDC (Johnson & Johnson Innovation – JJDC) Johnson & Johnson's corporate venture capital organization that finds transformative ideas and helps mature them into potential solutions for patients, investing across pharmaceuticals and medtech sectors at all stages from new company creation and seed-level startups to Series A and beyond, including private investments in public equity (PIPEs). JJDC maintains a portfolio of 40+ companies and has deployed over $1.8B since 2013.
• QuickFire Challenges Crowdsourcing platform that identifies, empowers, and enables potential breakthrough healthcare ideas from innovators across the globe, inviting entrepreneurs, companies at all stages of development, researchers, and students to apply for award funding, mentorship, and residency opportunities.
• Early Innovation Partnerships Program connecting early-stage startups and life science innovators to Johnson & Johnson's global resources and expertise through regional innovation teams located in Boston, London, South San Francisco, and Shanghai, to advance transformative science and technology across pharmaceutical and medtech sectors. Has resulted in 640+ strategic collaborations since 2013.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Two partnerships are on record, tiered core.

• JLABScoreStrategic or Co-development Partner · 17 April 2026OsseoLabs and Ramathibodi Hospital partnered with Johnson & Johnson Innovation - JLABS through the Osscentric Medical Technology Innovation Sandbox to bridge clinicians, engineers and Thai innovation to the global MedTech market.
• Resolve M TherapeuticscoreStrategic or Co-development Partner · 22 January 2026Resolve M Therapeutics was created through a strategic collaboration between Johnson & Johnson Innovation - JJDC and General Inception, leveraging insights from Professor Nir Hacohen's lab at the Broad Institute to build a pro-resolution platform for treating inflammatory diseases.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Pfizer Ventures: Pfizer's corporate venture capital arm investing across early-stage biotech and healthcare. Direct peer to JJDC with similar pharma-CVC mandate, recently co-invested alongside JJDC in TRexBio financing.
• Novartis Venture Fund: Novartis's dedicated corporate venture fund investing in life sciences therapeutics. Direct peer; co-led Citryll Series B alongside JJDC and Forbion, demonstrating overlap in immunology and inflammation theses.
• Leaps by Bayer: Bayer's impact-focused venture investment arm backing breakthrough life science and agriculture technologies. Direct peer; participated in SonoThera Series B alongside JJDC, with overlapping biotech and genetic medicine theses.
• Merck MRL Ventures Fund: Merck's corporate venture arm investing in early-stage therapeutics and platform technologies. Direct peer; led PAQ Therapeutics Series B with JJDC participation, sharing focus on protein degradation and oncology.
• Roche Venture Fund: Roche's corporate venture fund investing in diagnostics, therapeutics, and digital health. Direct peer with comparable pharma-CVC structure, therapeutic-area breadth, and incubation-adjacent activities.
• Sanofi Ventures: Sanofi's corporate venture capital arm investing across therapeutics and digital health. Direct peer with pharma-CVC mandate similar to JJDC, particularly focused on immunology and rare disease.
• Amgen Ventures: Amgen's corporate venture arm investing in early-stage biotech. Direct peer with comparable focus on innovative therapeutics and platform technologies serving pharma pipeline replenishment.
• AstraZeneca (incl. Alexion) CVC: AstraZeneca's corporate venture and innovation activities (including Alexion's rare disease investments). Direct peer with overlapping focus on oncology, immunology, and rare disease—key strategic areas also covered by JJDC.
• Eli Lilly (Lilly Ventures / Catalent): Eli Lilly's venture and external innovation activities. Direct peer in pharma CVC space; participated alongside JJDC in TRexBio financing, reflecting shared focus on immunology and metabolic disease platforms.
• Forbion: European life sciences-focused growth equity firm. Direct peer—co-led Citryll Series B with JJDC, sharing focus on immunology, oncology, and European biotech assets; comparable early-to-growth stage mandate.

Market position

Strengths4 records

Weaknesses3 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/jnjinnovation
• Instagraminstagram.com/jlabs
• LinkedInlinkedin.com/company/prominex-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments126 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Johnson & Johnson Innovation